BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCTX BriaCell Therapeutics Corp.

Trading 12-22 10:57:50 EST

9.21

+0.26

+2.91%

High9.29	Low8.93	Vol8.71K
Open9.05	D1 Closing8.95	Amplitude4.02%
Mkt Cap17.35M	Tradable Cap14.35M	Total Shares1.88M
T/O79.27K	T/O Rate0.56%	Tradable Shares1.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCTX","market":"US","secType":"STK","nameCN":"BriaCell Therapeutics Corp.","latestPrice":9.21,"timestamp":1766418711496,"preClose":8.95,"halted":0,"volume":8708,"delay":0,"floatShares":1558100,"shares":1883906,"eps":-33.785606,"marketStatus":"Trading","change":0.26,"latestTime":"12-22 10:57:50 EST","open":9.05,"high":9.29,"low":8.93,"amount":79269.986376,"amplitude":0.040223,"askPrice":9.41,"askSize":100,"bidPrice":9.21,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-33.785606,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"listingDate":1614142800000,"exchange":"NASDAQ","adjPreClose":8.95,"preHourTrading":{"tag":"盘前","latestPrice":8.95,"preClose":8.95,"latestTime":"08:12 EST","volume":5,"amount":44.800000000000004,"timestamp":1766409165686},"postHourTrading":{"tag":"盘后","latestPrice":9.12,"preClose":8.95,"latestTime":"19:00 EST","volume":289,"amount":2633.56,"timestamp":1766188807560},"volumeRatio":1.601472,"impliedVol":0.6056,"impliedVolPercentile":0.4167},"requestUrl":"/m/hq/s/BCTX","defaultTab":"news","newsList":[{"id":"2592909100","title":"“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909100","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909100?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061000,"startTime":"0","endTime":"0","summary":"Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVIDBriaCell’s ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207604/0/en/Eleven-clinical-trials-that-will-shape-medicine-in-2026-BriaCell-Phase-3-Trial-Featured-in-Nature-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","OS","BCTX","BK4139"],"gpt_icon":0},{"id":"2590346407","title":"BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346407","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346407?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:30","pubTimestamp":1765283400,"startTime":"0","endTime":"0","summary":"Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)Enrollment exceeding expectations with strong clinical site and patient i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202256/0/en/BriaCell-s-Phase-3-Patient-Enrollment-on-Track-for-1H2026-Topline-Data-Readout.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPI","BK4097","OS","MBC","BK4139","BCTX","BK4086"],"gpt_icon":0},{"id":"2588058732","title":"BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058732","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058732?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678600,"startTime":"0","endTime":"0","summary":"Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197795/0/en/BriaCell-to-Present-Phase-2-Survival-Phase-3-Clinical-Data-at-SABCS-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BCTX","PFS","BK4606","DTH","NLR","CPI","BK4139","BK4195"],"gpt_icon":0},{"id":"2586786064","title":"BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2586786064","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586786064?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:30","pubTimestamp":1764073800,"startTime":"0","endTime":"0","summary":"Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194231/0/en/BriaCell-to-Highlight-Positive-Phase-2-Phase-3-Clinical-Data-at-SABCS-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX"],"gpt_icon":0},{"id":"2584139460","title":"BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2584139460","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584139460?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:30","pubTimestamp":1763641800,"startTime":"0","endTime":"0","summary":"Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiaryPartnership expected to expand BriaPro's small-molecule pip","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191795/0/en/BriaCell-and-Receptor-AI-to-Collaborate-on-AI-Driven-Small-Molecule-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BCTX","BK4007","AI","BK4023","BK4587","BK4585","BK4543","LENZ","BK4139","BK4588","BK4539","BK4528"],"gpt_icon":0},{"id":"2584932715","title":"BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584932715","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584932715?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:30","pubTimestamp":1763469000,"startTime":"0","endTime":"0","summary":"Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study and updated survival data from the Phase 2 study of Bria-IMT plus immune check point inhibi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/18/3189891/0/en/BriaCell-Selected-to-Present-Phase-2-3-Clinical-Data-at-SABCS-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPI","BCTX"],"gpt_icon":0},{"id":"2581888267","title":"BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888267","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888267?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518600,"startTime":"0","endTime":"0","summary":"Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183561/0/en/BriaCell-Presents-Robust-Anti-Cancer-Activity-of-Bria-OTS-at-SITC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SITC","BCTX","BK4080","BK4231","IE00B12V2V27.USD","IE00BYQNZ168.SGD","01308","BK1541","SG9999011746.SGD","BK1103","BK4202","IE0003795394.USD","BK4139","NCI","IE0003851619.USD","IE00BYTNYN87.SGD"],"gpt_icon":0},{"id":"2580739996","title":"BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2580739996","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580739996?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:30","pubTimestamp":1762259400,"startTime":"0","endTime":"0","summary":"SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+ (breast cancer) and Bria-PROS+ (prostat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180205/0/en/BriaCell-to-Present-Robust-Anti-Cancer-Activity-of-Bria-OTS-in-Breast-and-Prostate-Cancer-Models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4139","BK4231","NCI","SITC","BK4202","BCTX"],"gpt_icon":0},{"id":"2578621859","title":"BriaCell’s Promising Breast Cancer Study: A Potential Game Changer?","url":"https://stock-news.laohu8.com/highlight/detail?id=2578621859","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578621859?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:16","pubTimestamp":1761585382,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics (($TSE:BCT)) announced an update on their ongoing clinical study. BriaCell Therapeutics is conducting a Phase I/II clinical s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacells-promising-breast-cancer-study-a-potential-game-changer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacells-promising-breast-cancer-study-a-potential-game-changer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"gpt_icon":0},{"id":"2577698253","title":"BriaCell says DSMB recommends continuation of Phase 3 Bria-IMT study","url":"https://stock-news.laohu8.com/highlight/detail?id=2577698253","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577698253?lang=en_us&edition=fundamental","pubTime":"2025-10-22 19:37","pubTimestamp":1761133033,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) Therapeutics announces that the independent Data Safety Monitoring Board has issued its fourth consecutive positive recommendation ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-says-dsmb-recommends-continuation-of-phase-3-bria-imt-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-says-dsmb-recommends-continuation-of-phase-3-bria-imt-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"gpt_icon":0},{"id":"2577827079","title":"BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2577827079","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577827079?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:50","pubTimestamp":1761047400,"startTime":"0","endTime":"0","summary":"79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/21/3170091/0/en/BriaCell-Adds-Key-Clinical-Sites-in-Phase-3-Metastatic-Breast-Cancer-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4086","MBC","BCTX","CPI","BK4097","OS","BK4139"],"gpt_icon":0},{"id":"2577822227","title":"BriaCell announces collaboration with MSK Accelerator Cohort program","url":"https://stock-news.laohu8.com/highlight/detail?id=2577822227","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577822227?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:36","pubTimestamp":1761046564,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) Therapeutics announces a collaboration with Memorial Sloan Kettering Cancer Center’s, MSK’s, Therapeutics Accelerator Cohort progra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-announces-collaboration-with-msk-accelerator-cohort-program-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-announces-collaboration-with-msk-accelerator-cohort-program-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2576856451","title":"BriaCell presents Phase 3 clinical biomarker data at ESMO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576856451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576856451?lang=en_us&edition=fundamental","pubTime":"2025-10-20 19:40","pubTimestamp":1760960449,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) Therapeutics announces encouraging clinical biomarker data in its ongoing pivotal Phase 3 study of Bria-IMT plus an immune check po...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-presents-phase-3-clinical-biomarker-data-at-esmo-2025-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-presents-phase-3-clinical-biomarker-data-at-esmo-2025-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"gpt_icon":0},{"id":"2575854332","title":"Promising Phase 3 Results for BriaCell’s Bria-IMT in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575854332","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575854332?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:05","pubTimestamp":1760371511,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maint...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-phase-3-results-for-briacells-bria-imt-in-metastatic-breast-cancer-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-phase-3-results-for-briacells-bria-imt-in-metastatic-breast-cancer-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","XBI","BK4139","BCTX","XLV","BK4581","LABU"],"gpt_icon":0},{"id":"2575517403","title":"BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575517403","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575517403?lang=en_us&edition=fundamental","pubTime":"2025-10-13 19:30","pubTimestamp":1760355000,"startTime":"0","endTime":"0","summary":"Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study of Bria-IMT in metastatic breast cancer (MBC)Positive delayed-type hypersensitivity (DTH) – a potenti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165447/0/en/BriaCell-to-Present-Positive-Clinical-Biomarker-Data-of-Phase-3-Study-at-ESMO-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","DTH","CPI","BK4139","BK4086","OS","MBC","BK4097","BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2572504121","title":"BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2572504121","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572504121?lang=en_us&edition=fundamental","pubTime":"2025-10-03 19:30","pubTimestamp":1759491000,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Oct.  03, 2025  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/03/3160903/0/en/BriaCell-to-Present-Bria-OTS-Preclinical-Data-at-SITC-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B12V2V27.USD","SITC","BK4139","BK1541","IE00BYTNYN87.SGD","BCTX","BK1103","01308","BK4231","SG9999011746.SGD","BK4080","IE00BYQNZ168.SGD"],"gpt_icon":0},{"id":"2562733893","title":"BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2562733893","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562733893?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:30","pubTimestamp":1756207800,"startTime":"0","endTime":"0","summary":"Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platformBria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/26/3139167/0/en/BriaCell-s-Bria-OTS-Mechanism-of-Action-Validated-in-Highly-Rated-Peer-Reviewed-Cancer-Journal.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4202","NCI","BCTX"],"gpt_icon":0},{"id":"2561497167","title":"BriaCell Therapeutics Says Board Approved Share Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2561497167","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561497167?lang=en_us&edition=fundamental","pubTime":"2025-08-22 01:01","pubTimestamp":1755795668,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  said Thursday that its board has approved a share consolidation on the basis of one new share for every 10 currently outstanding shares to ensure continued compliance with the listing requirements of The Nasdaq Capital Market.The consolidation is subject to approval by the Nasdaq and the Toronto Stock Exchange, and is expected to become effective on Aug. 25, the company said.Price: 0.66, Change: -0.03, Percent Change: -4.48","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NQmain","BK4139","BK4539","LENZ","BCTX"],"gpt_icon":0},{"id":"2561928064","title":"BriaCell Announces Proposed Effective Date of Share Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2561928064","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561928064?lang=en_us&edition=fundamental","pubTime":"2025-08-22 00:00","pubTimestamp":1755792000,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Aug.  21, 2025  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/21/3137357/0/en/BriaCell-Announces-Proposed-Effective-Date-of-Share-Consolidation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USAW.SI","PSQ","NQmain","TSYW.SI","TQQQ",".IXIC","NVIW.SI","USJW.SI","SQQQ","QID","MNQmain","QLD","BCTX","BK4139"],"gpt_icon":1},{"id":"2559602873","title":"BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2559602873","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559602873?lang=en_us&edition=fundamental","pubTime":"2025-08-13 19:30","pubTimestamp":1755084600,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Aug.  13, 2025  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/13/3132482/0/en/BriaCell-Selected-for-MSK-s-2025-Therapeutics-Accelerator-Program-for-Bria-OTS-for-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4539","LENZ","BCTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://briacell.com","stockEarnings":[{"period":"1week","weight":-0.0618},{"period":"1month","weight":0.2677},{"period":"3month","weight":-0.0219},{"period":"6month","weight":-0.7075},{"period":"1year","weight":-0.898},{"period":"ytd","weight":-0.8944}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.05711},{"month":2,"riseRate":0.25,"avgChangeRate":-0.068829},{"month":3,"riseRate":0.6,"avgChangeRate":0.067532},{"month":4,"riseRate":0.2,"avgChangeRate":-0.075667},{"month":5,"riseRate":0,"avgChangeRate":-0.209369},{"month":6,"riseRate":0.6,"avgChangeRate":0.078701},{"month":7,"riseRate":0.4,"avgChangeRate":-0.192928},{"month":8,"riseRate":1,"avgChangeRate":0.139099},{"month":9,"riseRate":0.6,"avgChangeRate":0.155119},{"month":10,"riseRate":0,"avgChangeRate":-0.140813},{"month":11,"riseRate":0.6,"avgChangeRate":0.110284},{"month":12,"riseRate":0.2,"avgChangeRate":-0.148788}],"exchange":"NASDAQ","name":"BriaCell Therapeutics Corp.","nameEN":"BriaCell Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BriaCell Therapeutics Corp.,BCTX,BriaCell Therapeutics Corp.股票,BriaCell Therapeutics Corp.股票老虎,BriaCell Therapeutics Corp.股票老虎国际,BriaCell Therapeutics Corp.行情,BriaCell Therapeutics Corp.股票行情,BriaCell Therapeutics Corp.股价,BriaCell Therapeutics Corp.股市,BriaCell Therapeutics Corp.股票价格,BriaCell Therapeutics Corp.股票交易,BriaCell Therapeutics Corp.股票购买,BriaCell Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}